Wilms Tumor 1 (WT1) Antikörper

Antigen: Wilms Tumor 1 (WT1)

Synonyme: GUD, WAGR, WT33, WIT-2, WT1, WT, wt1-A, xWT1, CWT1, WT-1, wt1, MGC152697, zgc:152697, si:ch211-160j6.3, gud, wagr, wt-1, wt33, xwt1, wit-2

Klonalität: Monoklonal (6F-H2)

Wirt: Maus

Reaktivität: Human

Applikation: Immunhistochemie (Paraffinschnitte) (IHC (p))

Produktnummer: ABIN125232

Produktbeschreibung

Weitere Bezeichnung: Wilms Tumor 1 Protein (WT1)

Immunogen: BALB/C mice were injected with truncated human WT1 protein corresponding to N-terminal amino acids 1-181.

Isotyp: IgG1  (Passende Sekundärantikörper)

Klon: 6F-H2

Spezifität: Wilms' Tumor (WT1), is a gene involved in the induction of Wilms

Anwendungen

Applikationshinweise: Titer/Working Dilution: This antibody may be diluted to a titer of 1:15-1:25 in an ABC method. However, depending on the staining conditions employed, we suggest that final dilution should be determined by the user. Staining Protocol: We suggest an incubation period of 30 to 60 minutes at room temperature. However, depending upon the fixation conditions and the staining system employed, optimal incubation should be determined by the user. Formalin fixed paraffin embedded tissue sections require high temperature antigen unmasking with 10 mM Citrate buffer, pH 6.0 prior to immunostaining. Positive Control: Wilms

Konzentration: 100ug/ml approximately

Buffer: This antibody is supplied as tissue culture supernatant containing BSA and sodium azide as preservative.

Lagerung: Store the antibody at 2-8o c. Do not use it beyond the expiration date stated on the label.

Beschränkungen: Für Forschungszwecke. Als CE-zertifizierter Antikörper in der Europäischen Union für In Vitro Diagnostik (IVD) zugelassen.

Publikationen

Publikationen: Haber, Buckler: "WT1: a novel tumor suppressor gene inactivated in Wilms' tumor." in: The New biologist, Vol. 4, Issue 2, pp. 97-106, 1992 (PubMed).

Menssen, Renkl, Rodeck et al.: "Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias." in: Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, Vol. 9, Issue 6, pp. 1060-7, 1995 (PubMed).

Kumar-Singh, Segers, Rodeck et al.: "WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis." in: The Journal of pathology, Vol. 181, Issue 1, pp. 67-74, 1997 (PubMed).